Ovid Therapeutics Inc.
OVID· Nasdaq
Released Aug 4, 2023, before the open
10-Q filed Aug 4, 2023, 35 days after period end · 0001628280-23-027430
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $75.00K | $0.00 | $0.00 | — |
| Net Income | -$12.41M | -$14.59M | -$15.79M | -$22.55M |
| EPS Diluted |
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
| -$0.18 |
| -$0.21 |
| -$0.23 |
| -$0.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.